170 related articles for article (PubMed ID: 38216364)
41. [Sodium-glucose-cotransporter 2 inhibitor-associated euglycaemic diabetic ketoacidosis].
Fisker F; Møller N; Lauritzen ES
Ugeskr Laeger; 2019 May; 181(21):. PubMed ID: 31124439
[TBL] [Abstract][Full Text] [Related]
42. Sodium-Glucose Cotransporter-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis After Orthotopic Heart Transplant in a Prediabetic Patient: A Case Report.
Cha BM; Davoudi R; DiVita MC; Fan AM; Kamath MY
Transplant Proc; 2021 Oct; 53(8):2636-2639. PubMed ID: 34531071
[TBL] [Abstract][Full Text] [Related]
43. Euglycemic diabetic ketoacidosis.
Barski L; Eshkoli T; Brandstaetter E; Jotkowitz A
Eur J Intern Med; 2019 May; 63():9-14. PubMed ID: 30910328
[TBL] [Abstract][Full Text] [Related]
44. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Colacci M; Fralick J; Odutayo A; Fralick M
Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
[TBL] [Abstract][Full Text] [Related]
45. Euglisemic diabetic ketoacidotic coma caused by dapagliflozin.
Karakaya Z; Topal FE; Topal F; Payza U; Akyol PY
Am J Emerg Med; 2018 Nov; 36(11):2136.e1-2136.e2. PubMed ID: 30150107
[TBL] [Abstract][Full Text] [Related]
46. [Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].
Menghoum N; Oriot P; Hermans MP; Mariage JL
Rev Med Interne; 2020 Apr; 41(4):226-231. PubMed ID: 31866073
[TBL] [Abstract][Full Text] [Related]
47. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
Dull RB; Spangler ML; Knezevich EL; Lau BM
J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
[TBL] [Abstract][Full Text] [Related]
48. Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus.
Chauhan S; Manov A; Dhillon GS; Shah P
Cureus; 2023 Jan; 15(1):e33892. PubMed ID: 36819400
[TBL] [Abstract][Full Text] [Related]
49. Can euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors be avoided in Covid-19 and other acute Infections?
Pilianidis G; Papanastasiou G; Tikoudi P; Themistocleous A; Farmakis G; Dolianitis K
Eur J Case Rep Intern Med; 2024; 11(3):004282. PubMed ID: 38455692
[TBL] [Abstract][Full Text] [Related]
50. Self-Induced Euglycemic Diabetic Ketoacidosis: When to Stop the Drip.
Zughaib MT; Patel K; Leka M; Affas S
Cureus; 2022 Jan; 14(1):e21768. PubMed ID: 35251838
[TBL] [Abstract][Full Text] [Related]
51. A Case Report: Euglycemic Diabetic Ketoacidosis Presenting as Chest Pain in a Patient on a Low Carbohydrate Diet.
Dorcely B; Nitis J; Schwartzbard A; Newman JD; Goldberg IJ; Sum M
Curr Diabetes Rev; 2021; 17(2):243-246. PubMed ID: 32178617
[TBL] [Abstract][Full Text] [Related]
52. COVID-19-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes on SGLT2 inhibitor: a case report.
Batista DV; Vieira CAFA; Costa TA; Lima EG
Diabetol Int; 2021 Jul; 12(3):313-316. PubMed ID: 33133998
[TBL] [Abstract][Full Text] [Related]
53. SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review.
Mahfooz RS; Khan MK; Al Hennawi H; Khedr A
Cureus; 2022 Jun; 14(6):e26267. PubMed ID: 35911365
[TBL] [Abstract][Full Text] [Related]
54. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review.
Sampani E; Sarafidis P; Dimitriadis C; Kasimatis E; Daikidou D; Bantis K; Papanikolaou A; Papagianni A
BMC Nephrol; 2020 Jul; 21(1):276. PubMed ID: 32669085
[TBL] [Abstract][Full Text] [Related]
55. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
56. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks.
Perry RJ; Shulman GI
J Biol Chem; 2020 Oct; 295(42):14379-14390. PubMed ID: 32796035
[TBL] [Abstract][Full Text] [Related]
57. Sodium-glucose co-transporter-2 inhibitor-associated euglycemic diabetic ketoacidosis that prompted the diagnosis of fulminant type-1 diabetes: A case report.
Yasuma T; Okano Y; Tanaka S; Nishihama K; Eguchi K; Inoue C; Maki K; Uchida A; Uemura M; Suzuki T; D'Alessandro-Gabazza CN; Gabazza EC; Yano Y
World J Clin Cases; 2021 May; 9(13):3163-3169. PubMed ID: 33969104
[TBL] [Abstract][Full Text] [Related]
58. Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors.
Jeon JY; Kim SK; Kim KS; Song SO; Yun JS; Kim BY; Kim CH; Park SO; Hong S; Seo DH; Seo JA; Noh JH; Kim DJ;
Diabetes Metab; 2019 Oct; 45(5):453-457. PubMed ID: 30639566
[TBL] [Abstract][Full Text] [Related]
59. Euglycemic Diabetic Ketoacidosis in the Surgical Patient.
McCabe DE; Strollo BP; Fuhrman GM
Am Surg; 2023 Apr; 89(4):1083-1086. PubMed ID: 33316172
[TBL] [Abstract][Full Text] [Related]
60. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis.
Sitina M; Lukes M; Sramek V
BMC Endocr Disord; 2023 Apr; 23(1):81. PubMed ID: 37060078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
